Aluminium-magnesium silicate inhibits parvovirus and cures infected dogs

Ezeibe Maduike C. O., Nwaogu Innocent C., Nwigwe Ada N., Okorafor Obianuju N., Eze James I., Ngene Augustine A.

.

DOI: 10.4236/health.2010.210179                

Abstract

Ability of a synthetic Aluminium-Magnesium Silicate [AMS] to inhibit activities of canine parvovirus [CPV] was investigated in vitro and in vivo. Five samples of CPV isolated in Nigeria, were each incubated with equal amount of a synthetic AMS on a volume to weight [v/w] basis, for one hour and then centrifuged. Viral titres of the supernatants were tested by the haemagglutination [HA] test and their mean titre compared with mean titre of portions of same viral samples, not incubated with the AMS. Also, five puppies and five adult dogs infected with the parvovirus isolates were treated by dosing each with 400 mg/kg of a drug formulation that has 12% AMS per os for seven days. As control, five puppies and five adult dogs from same class as the experimental dogs were similarly infected but were not treated. Incubating parvovirus with AMS reduced its load from mean HA titre 825.6 ± 261.1 to mean HA, 270.8 ± 132.1 [p < 0.05]. Also treating parvovirus infected dogs with a 12% AMS drug formulation reduced mortality due to the virus from 100% to zero [p < 0.01].

Keywords

Aluminium-Magnesium Silicate; Canine Parvovirus Haemagglutination Test

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Baker, I.K., Povey, R.C. and Voigt, D.R. (1983) Response of mink, skunk, raccon and red fox to Canine parvovirus and feline panleukopaenia virus in Ontario. Journal of Complementary Medicine, 47, 188-197.
[2]	Nigel, D., Easton, A. and Leppard, K. (2007) Introduction to morden virology. Venetia Saunders, Kindle Store
[3]	Ford, R.B. (1988) Clinical signs and diagnosis in small animal practice. Churchill Livingstone, New York.
[4]	Kamalu, B.P. (1982) Canine parvovirus infections in Nigeria. Journal of Small Animal Practice, 26(11), 663- 668.
[5]	Khan, C. and Line, S. (2005) The Merk veterinary manual. 9th Edition, Merck and Co, New Jersey.
[6]	Greene, C.E. (1984) Clinical microbiology and infectious diseases of dogs and cats. W. B. Saunders, Philadelphia.
[7]	Appel, M.J. and Parish, C.R. (1987) Canine Parvovirus type-2 of carnivores. Elsevier, The Netherlands.
[8]	Pollock, R.V.H. (1984) The Parvovirus PART 11, Canine Parvovirus. Comparat. Cont. Educ., 6(1), 653-664.
[9]	Thompson, N., McLandish, I.A.P., Cornwell, N.J.C. (1979) Isolation of parvovirus from dogs in Britain. Veterinary Record, 105(8), 167-168.
[10]	Walsh, F.M. and Ames, S.G.B. (2004) Microbiology and Drug resistance mechanism of fully resistant pathogens. Nature Reviews Microbiology, 56(1), 65-79.
[11]	Payne, D. and Thomas, A. (2004) Aspects of the diagnosis, pathogenesis and epidemiology of canine parvovirus. Australian Veterinary Journal, 60(11), 197-200.
[12]	Carmichael, L. (2005) Neonatal viral infections of pups. International Veterinary Information Service. Ithaca, New York.
[13]	Vanderbilt, R.T. (1992) Veegum the versatile ingredient for pharmaceutical formulation. RT Vanderbilt Co., Inc. Technical Literature, Veegum.
[14]	Jacyna, M.R. and Wormsley, K.G. (2005) Aluminium- Magnesium Silicate used in drug formulation and cosmetic. Bulletin of Materials Science, 24(6), 377-382.
[15]	Windholz, M., Budavan, S. and Fertig, M. (1978) The Merck index. Merck and Co Inc., New Jersey.
[16]	Foster, E. and Smith, K. (2007) Aluminium-Magnesium Silicate is used as antacids, antiulcer and control of diarrhoeas. Journal of Renal Nutrition, 4(2), 50-53.
[17]	Schils, S. (2002) The use of montmorillonite in the fight against harmful affects of ammonia. Journal of Renal Nutrition, 4(2), 32-36.
[18]	Cann, A.J. (1993) Principles of molecular biology. Academic Press, San Diego, USA.
[19]	Ezeibe, M.C.O. (2006) Admacine?. Federal Republic of Nigeria Patents and Designs Act. Cap 344 LFN 1990, NO. RP 16446.
[20]	Ijabo, O. (2006) Effect of synthetic aluminium magnesium silicate on pestes des petits ruminants and newcastle disease virus. M. Sc. Thesis, University of Nigeria, Nsukka, Nigeria.
[21]	Ezeibe, M.C.O., Okoroafor, O.N., Ijabo, O., Ukomadu, N. M., Ngene, A.A., Eze, J.I and Orajaka, L.J.E. (2010). Haemagglutination and haemagglutination-inhibition titre of egg drop syndrome-76 virus treated with aluminium-magnesium silicate. Animal Science, 4(3), 67-70.
[22]	Ezeibe, M.C.O., Mbuko, I.J., Okoroafor, O.N., Okon- kwo, A.C., Animoke, P., Orajaka, L.J.E and Ngene, A.A (2009a) In vitro and in vivo effects of aluminium-mag- nesium silicate on infectious bursal disease virus of chicken. Anim. Sc. Rep., 3(4), 132-137.
[23]	Ezeibe, M.C.O., Ijabo, O., Okoroafor, O.N., Orajaka, L.J. E. Ukomadu, N.M., Chukwu, O.S. and Ngene, A.A. (2009b) Antiviral effects of aluminium-magnesium silicate on Peste des Petits Ruminants Virus. Anim. Sc. Rep., 3(4), 141-147.
[24]	Wosu, L.O. (1984) Standardization of red blood cells for haemagglutination test and removal of naturel agglutin- ins. Nigerian Veterinary Journal, 13(1), 39-42.
[25]	Chernicoff, S. and Venkatakrishnan, R. (1995) Introduction to physical geology. Worth Pub, New York.
[26]	Galindo, L.A. and Cereso, P. (2006) Compositional te- chnical and safety specification of clay to be used as pharmaceutical and cosmetic products. Journal of Renal Nutrition, 2(1), 38-40.
[27]	Greene, C. E. (1990) Infectious diseases of dogs and cats. 1st Edition, W. B. Saunders, Philadephia.
[28]	Murray, K.R. (2000) Harpers biochemistry, McGraw Hill, New York, USA.